2018-09-24 Comments Off on FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of Nuplazid (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of Nuplazid (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis SAN DIEGO–(BUSINESS WIRE)–Sep. 20, 2018– Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)